Ozempic Could Crush the Junk Food Industry. But It Is Fighting Back.
Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder
The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis
The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis
Why Do Obesity Drugs Seem to Treat so Many Other Ailments?
NYC law student addicted to cheese went to nearly $6K-per-week rehab
They Promoted Body Positivity. Then They Lost Weight: Do plus-size influencers owe their followers an explanation when their bodies change?
Substantial Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series
GWAS of random glucose in 476,326 individuals provide insights into diabetes pathophysiology, complications and treatment stratification
People on Drugs Like Ozempic Say Their ‘Food Noise’ Has Disappeared: For some, it’s a startling side effect
Brain responses to nutrients are severely impaired and not reversed by weight loss in humans with obesity: a randomized crossover study
What the Scientists Who Pioneered Weight-Loss Drugs Want You to Know
I lost 40 pounds on Ozempic. But I’m left with even more questions.
Ozempic’s Next Act: People taking the drug for weight loss say they have also stopped drinking, smoking, shopping, and even nail-biting
Effects of liraglutide on depressive behavior in a mouse depression model and cognition in the probe trial of Morris water maze test
Feasibility of Exenatide, a GLP-1R Agonist, for Treating Cocaine Use Disorder: A Case Series Study
Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats
The potential antidepressant effect of antidiabetic agents: New insights from a pharmacovigilance study based on data from the reporting system databases FAERS and VigiBase
Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions
Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats
Glucagon-like Peptide 1 Receptor Activation Inhibits Microglial Pyroptosis via Promoting Mitophagy to Alleviate Depression-like Behaviors in Diabetic Mice
Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential
Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder
Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats
GABA neurons in the nucleus tractus solitarius express GLP-1 receptors and mediate anorectic effects of liraglutide in rats
Glucagon-like peptide-1 receptors within the nucleus of the solitary tract regulate alcohol-mediated behaviors in rodents
Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys
Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies
Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis
Liraglutide for psychiatric disorders: clinical evidence and challenges
Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon-like peptide 1 receptor agonists?
Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats
No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia
Central & peripheral glucagon-like peptide-1 receptor signaling differentially regulate addictive behaviors
Glucagon-like peptide-1 (GLP-1) receptor agonist prevents development of tolerance to anti-anxiety effect of ethanol and withdrawal-induced anxiety in rats
Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect
Liraglutide: short-lived effect on gastric emptying—long lasting effects on body weight
Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis
Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4
2024-qeadan-gipandglp1dietdrugprotectiveeffectsonopioidandalcoholoverdose.jpg
https://longreads.com/2024/04/18/crohns-life-without-eating/
https://www.morganstanley.com/ideas/obesity-drugs-food-industry
https://www.npr.org/sections/health-shots/2023/08/28/1194526119/ozempic-wegovy-drinking-alcohol-cravings-semaglutide
https://www.theatlantic.com/ideas/archive/2023/11/ozempic-wegovy-social-revolution-weight-loss/676002/
https://www.wsj.com/health/pharma/a-weight-loss-drug-changed-my-life-will-it-solve-my-problem-aeb79260
The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis
%252Fdoc%252Fpsychiatry%252Falcoholism%252F2024-qeadan.pdf.html
They Promoted Body Positivity. Then They Lost Weight: Do plus-size influencers owe their followers an explanation when their bodies change?
https%253A%252F%252Fwww.nytimes.com%252F2024%252F02%252F26%252Fstyle%252Fbody-positive-influencers-weight-loss.html.html
Substantial Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series
%252Fdoc%252Flongevity%252Fglp%252Fsemaglutide%252F2023-richards.pdf.html
Brain responses to nutrients are severely impaired and not reversed by weight loss in humans with obesity: a randomized crossover study
What the Scientists Who Pioneered Weight-Loss Drugs Want You to Know
https%253A%252F%252Fwww.wired.com%252Fstory%252Fobesity-drugs-researcher-interview-ozempic-wegovy%252F.html
Ozempic’s Next Act: People taking the drug for weight loss say they have also stopped drinking, smoking, shopping, and even nail-biting
https%253A%252F%252Fwww.theatlantic.com%252Fhealth%252Farchive%252F2023%252F05%252Fozempic-addictive-behavior-drinking-smoking%252F674098%252F.html
Glucagon-like peptide-1 receptors within the nucleus of the solitary tract regulate alcohol-mediated behaviors in rodents
https%253A%252F%252Fwww.sciencedirect.com%252Fscience%252Farticle%252Fpii%252FS0028390819300541.html
